Compare BridgeBio Pharma Inc (BBIO) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.58. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | QDTY | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $90.17 | $46.71 |
52-Week Low | $47.29 | $36.57 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
QDTY trades at $39.78, up 1.02% today, with a bearish technical signal from moving averages and mixed oscillators. The stock shows consistent weekly dividend distributions, but key valuation and profitability ratios are unavailable. Recent news highlights ongoing dividend announcements from YieldMax ETFs, indicating a focus on income generation.
The outlook is cautious due to bearish technicals and lack of fundamental data; risks include market volatility and dependency on dividend strategy. Investors should seek updated financials for a clearer assessment of growth potential and sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
